Daymark Wealth Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Daymark Wealth Partners’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$243K	Buy	+482	New	+$255K	0.01%	763

Other funds holding MDGL

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $33.4B AUM 56.97% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $54.9B AUM 27.38% 1-Year Est. Return

Daymark Wealth Partners's MDGL Position: Q3 2026 in Review

Daymark Wealth Partners opened a new position in Madrigal Pharmaceuticals (MDGL) in Q3 2026: 482 shares worth $243K. The stake represents 0.01% of the portfolio and ranks #763 among its holdings.

332 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

Daymark Wealth Partners held 482 shares of Madrigal Pharmaceuticals worth $243K as of Q3 2026.
Madrigal Pharmaceuticals was a new Daymark Wealth Partners position in Q3 2026.
Madrigal Pharmaceuticals made up 0.01% of Daymark Wealth Partners's portfolio in Q3 2026, its #763 holding.
332 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Daymark Wealth Partners's 13F filing for Q3 2026, filed 4 Nov 2026.